MediciNova (MNOV)
Develops in-licensed small molecules across neurodegenerative, metabolic, and fibrotic diseases.
Something off on this page? Send us feedback.
Develops in-licensed small-molecule therapeutics for serious neurodegenerative, metabolic, and fibrotic diseases. Reports service revenue from a clinical-research support arrangement rather than product sales, while its broader program set relies on two licensed molecules.
Develops in-licensed small-molecule therapeutics for serious diseases with unmet medical needs, centered on MN-166 (ibudilast) and MN-001 (tipelukast). Its clinical work spans ALS, degenerative cervical myelopathy, progressive multiple sclerosis, Long COVID, substance dependence, and metabolic and fibrotic disease. No products are approved for commercial sale.
Operates from California with legal entities in Japan, Germany, and Canada, while development focuses primarily on the U.S. market. Clinical execution relies on research institutions, government-supported studies, and outside providers rather than a large internal organization.
Builds multiple indication programs from two licensed molecules, so clinical, regulatory, supply, intellectual-property, and licensing outcomes for either compound can affect several programs. Existing license agreements include potential development milestones and future sales royalties.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 17, 2026 | Roth Capital | Initiate | Rating: —Target: — | Target: $6 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $25.4M · Total debt $117.0K · Total assets $40.4M · Shareholders' equity $37.3M
- Revenue
- $458.4K
- Operating income
- −$2.5M
- Net income
- −$2.3M
No dividends on record.
| Institutions | 10.67% | 5.25M shares | |
|---|---|---|---|
| 30 holders · as of Jun 30, 2026 | |||
| Other | 89.33% | 43.97M shares | |
| remainder | |||
49.22M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Essex Woodlands Management, Inc.Institution | 2.25% | 1.11M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.53% | 752,091 | as of Jun 30, 2026 |
Citigroup IncInstitution | 1.29% | 635,715 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 1.24% | 609,052 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 1.10% | 539,312 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Biogen
Approved SOD1-ALS therapy and a broad-ALS pipeline entrant.
- Madrigal Pharmaceuticals
Approved MASH therapy with large commercial and trial advantages.
- Ionis Pharmaceuticals
Phase 3 FUS-ALS program targeting a genetically defined subgroup.
- Novo Nordisk (ADR)
Phase 3 MASH program backed by a global metabolic-care leader.
- AllianceBernstein
Prospective Phase 3 ALS program with masitinib.
- Amarin (ADR)
Established triglyceride-lowering therapy for overlapping metabolic patients.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MediciNova | $3.06 | −7.27% | $162.4M | — | — | 176.5 | +241.0% |
| Biogen | $222.04 | +1.36% | $32.37B | 38.8 | 16.7 | 3.3 | +3.4% |
| Madrigal Pharmaceuticals | $520.72 | −0.24% | $12.06B | — | — | 9.4 | +71.2% |
| Ionis Pharmaceuticals | $44.82 | −0.19% | $7.46B | — | — | 8.5 | −40.7% |
| Novo Nordisk (ADR) | $39.64 | −0.40% | $176.83B | 9.9 | 16.3 | 3.5 | +1.3% |
| AllianceBernstein | $36.28 | −0.25% | $3.39B | 10.8 | 10.0 | 9.9 | +5.1% |
| Amarin (ADR) | $13.73 | +1.85% | $278.8M | — | — | 1.5 | −42.0% |
| Median | 10.8 | 16.3 | 6.0 | +2.4% |